DNTH (STOCKS)
Dianthus Therapeutics, Inc. Common Stock
$90.000000
+0.230000 (+0.26%)
Prev close: $89.770000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Biotechnology
- CEO
- Marino Garcia
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $4,757.38M
- Employees
- 78
- P/E (TTM)
- -21.88
- P/B (TTM)
- 7.86
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
10
Strong Buy
11
Buy
1
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Dec 2025 (Q4)
|
$-1.43 | $-1.10 | -0.3328 | -30.33% |
|
Sep 2025 (Q3)
|
$-0.97 | $-0.88 | -0.0904 | -10.28% |
|
Jun 2025 (Q2)
|
$-0.88 | $-0.89 | +0.0091 | +1.02% |
|
Mar 2025 (Q1)
|
$-0.82 | $-0.87 | +0.0460 | +5.31% |
Financial Statements
| Revenues | $2.04M |
| Benefits Costs and Expenses | $164.37M |
| Costs And Expenses | $164.37M |
| Nonoperating Income/Loss | $15.60M |
| Operating Expenses | $179.97M |
| Research and Development | $145.64M |
| Other Operating Expenses | $34.33M |
| Operating Income/Loss | -$177.93M |
| Income/Loss From Continuing Operations After Tax | -$162.34M |
| Income/Loss From Continuing Operations Before Tax | -$162.34M |
| Income Tax Expense/Benefit | $0.00 |
| Net Income/Loss | -$162.34M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$162.34M |
| Net Income/Loss Available To Common Stockholders, Basic | -$162.34M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$4.20 |
| Diluted Earnings Per Share | -$4.20 |
| Basic Average Shares | 38,617,580 |
| Diluted Average Shares | 38,617,580 |
| Assets | $530.92M |
| Current Assets | $409.44M |
| Cash | $50.25M |
| Other Current Assets | $359.19M |
| Noncurrent Assets | $121.48M |
| Fixed Assets | $296.00K |
| Other Non-current Assets | $121.19M |
| Liabilities | $37.52M |
| Current Liabilities | $30.73M |
| Accounts Payable | $9.73M |
| Wages | $9.52M |
| Other Current Liabilities | $11.49M |
| Noncurrent Liabilities | $6.79M |
| Equity | $493.40M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $493.40M |
| Liabilities And Equity | $530.92M |
| Net Cash Flow From Operating Activities | -$129.06M |
| Net Cash Flow From Operating Activities, Continuing | -$129.06M |
| Net Cash Flow From Investing Activities | -$122.83M |
| Net Cash Flow From Investing Activities, Continuing | -$122.83M |
| Net Cash Flow From Financing Activities | $280.13M |
| Net Cash Flow From Financing Activities, Continuing | $280.13M |
| Net Cash Flow | $28.23M |
| Net Cash Flow, Continuing | $28.23M |
| Comprehensive Income/Loss | -$161.95M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$161.95M |
| Other Comprehensive Income/Loss | $383.00K |
| Other Comprehensive Income/Loss Attributable To Parent | $383.00K |